[1] Troelstra MA, Witjes JJ, Dijk AM, et al. Assessment of imaging modalities against liver biopsy in nonalcoholic fatty liver disease: The Amsterdam NAFLD-NASH cohort. J Magn Reson Imaging, 2021, 54(6): 1937-1949. [2] Jarvis H, Craig D, Barker R, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med, 2020, 17(4): e1003100. [3] Ma Z, Xu C, Kang X, et al. Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study. J Transl Med, 2020, 18(1): 133. [4] Miele L, Alberelli MA, Martini M, et al. Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. Transl Res, 2021, 23(1): 24-38. [5] Zhu F, Li X. Fructose intake is not associated to the risk of hepatic fibrosis in patients withnon-alcoholic fatty liver disease (NAFLD). Clin Nutr, 2021, 40(6): 3827. [6] Amerikanou C, Papada E, Gioxari A, et al. Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action. Pharmacol Res, 2021, 17(1): 105753. [7] 中国肝病学会脂肪肝与酒精性肝病研究组. 非酒精性脂肪性肝病诊疗指南. 中华肝脏病杂志, 2006, 14(3): 161-163. [8] Li Y, Xu J, Lu Y, et al. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. Cell Metab, 2021, 33(10): 2004-2020. [9] Ajaz S, McPhail MJ, Gnudi L, et al. Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion, 2021, 57(5): 119-130. [10] 黄蝶, 田昊宇, 李异玲. 非酒精性脂肪性肝病血清标志物研究进展. 实用肝脏病杂志, 2022, 25(2): 297-300. [11] Anderson O, Guttilla Reed IK. Regulation of cell growth and migration by miR-96 and miR-183 in a breast cancer model of epithelial-mesenchymal transition. PLoS One, 2020, 5(5): e0233187. [12] Chava S, Reynolds CP, Pathania AS, et al. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. Mol Oncol, 2020, 14(1): 180-196. [13] Zhou X, Yuan Y, Teng F, et al. Obesity-induced upregulation of microRNA-183-5p promotes hepatic triglyceride accumulation by targeting the B-cell translocation gene 1. Life Sci, 2021, 26(8): 119011. [14] Yan S, Wang H, Chen X, et al. MiR-182-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-C. Cancer Lett, 2020, 488(28): 18-26. [15] Chen SJ, Ning H, Ishida W, et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem, 2021, 281(30): 21183-21197. [16] Chandel R, Saxena R, Das A, et al. Association of rno-miR-183-96-182 cluster with diethyinitrosamine induced liver fibrosis in Wistar rats. J Cell Biochem, 2018, 119(5): 4072-4084. [17] Wang H, Ma Z, Liu X, et al. MiR-183-5p is required for non-small cell lung cancer progression by repressing PTEN. Biomed Pharmacother, 2019, 111(5): 1103-1111. [18] Chen D, Xu L, Wu J, et al. Downregulating miR-96-5p promotes proliferation, migration, and invasion, and inhibits apoptosis in human trophoblast cells via targeting DDAH1. Reprod Biol, 2021, 21(1): 100474. [19] Derany MO, AbdelHamid SG. Upregulation of miR-96-5p by bone marrow mesenchymal stem cells and their exosomes alleviate non-alcoholic steatohepatitis: Emphasis on caspase-2 signaling inhibition. Biochem Pharmacol, 2021, 190(8): 114624. [20] Dong XZ, Song Y, Lu YP, et al. Sanguinarine inhibits the proliferation of BGC-823 gastric cancer cells via regulating miR-96-5p/miR-29c-3p and the MAPK/JNK signaling pathway. J Nat Med, 2019, 73(4): 777-788. [21] Fisher L. Retraction: MiR-182-5p and miR-96-5p increased hepatocellular carcinoma cell mobility, proliferation and cisplatin resistance partially by targeting RND3. RSC Adv, 2021, 11(7): 4166. |